Consequently, correcting aberrations in the renin–angiotensin–aldosterone system (RAAS) has emerged as a foremost therapeutic approach to decelerate CKD progression, often achieved by angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers, either individually or in combination [18,19]. The gene discussed is ACE; the disease is chronic kidney disease.